ALL libraries (COBIB.SI union bibliographic/catalogue database)
  • Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients : results of a 1-year follow-up study from the CERERRA collaboration
    Chatzidionysiou, Katerina ...
    Objectives: To compare the effectiveness and safety of rituximab alone or in combination with either methotrexate or leflunomide. Methods: 10 European registries submitted anonymised datasets with ... baseline, 3, 6, 9 and 12-month clinical data from patients who started rituximab. Results: 1195 patients weretreated with rituximab plus methotrexate, 177 with rituximab plus leflunomide and 505 with rituximab alone. Significantly more patients achieveda European League Against Rheumatism good response at 6 months when treated with rituximab plus leflunomide (29.1%) compared with rituximab plus methotrexate (21.1%) and rituximab alone (19.3%; p=0.02 and p=0.01, respectively). Similar results were observed at 12 months. Adverse events occurred in 10.2%, 13.2% and 13.9% of patients on rituximab plus leflunomide, rituximab plus methotrexate and rituximab alone, respectively. Conclusions: Leflunomide is an effective and safe alternative to methotrexate as concomitant treatment with rituximab. Slightly better results were obtained bythe combination of rituximab and leflunomide than rituximab and methotrexate, raising the possibility of a synergistic effect of leflunomide and rituximab.
    Source: Annals of the Rheumatic Diseases. - ISSN 0003-4967 (Vol. 71, iss. 3, 2012, str. 374-377)
    Type of material - article, component part
    Publish date - 2012
    Language - english
    COBISS.SI-ID - 29859801
    DOI